Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants
A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

NCT05036512

CompletedPhase 1

Sponsor: Pfizer

Conditions: Sickle Cell Disease

Interventions: GBT021601

Countries: United States, Australia

This first in human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and food effect of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in healthy participants.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Healthy males and females ≥ 18 to ≤ 55 years of age
* Body mass index ≥ 18.0 to ≤ 30.0 kg/m2
* Body weight ≥ 50 kg at screening and Day -1

Exclusion Criteria:

\- Positive pregnancy test or currently breastfeeding.
Locations (4)
  • San Antonio, Texas, United States
  • Nedlands, Western Australia, Australia
  • Nedlands, Western Australia, Australia
  • North Perth, Western Australia, Australia